Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals and Kyowa Hakko Kogyo have formed an exclusive alliance to develop and commercialize ALN-RSV01, an RNAi therapeutic in Phase II clinical development by Alnylam for the treatment of respiratory syncytial virus infection, in Japan and other major markets in Asia.
Subscribe to our email newsletter
Under the terms of the collaboration, Kyowa Hakko will pay Alnylam $15 million in an upfront cash payment and up to an additional $78 million in development and sales milestone payments. Upon commercialization, Alnylam will receive double-digit royalties from Kyowa Hakko based on the sales of ALN-RSV01 in this territory.
The partnership also includes additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program. Alnylam retains all development and commercialization rights worldwide excluding Asia.
Yuzuru Matsuda, CEO of Kyowa Hakko, said: “We are looking forward to working with Alnylam in the development and commercialization of ALN-RSV01 in Japan and other major markets in Asia. We are excited to have the opportunity in delivering the benefit of this novel medicine to patients in Asia through the partnership with Alnylam.”